FOSUN PHARMA Shares Surge Over 5% as Annual Net Profit Climbs 21.69% to 3.37 Billion Yuan

Deep News03-25

FOSUN PHARMA (02196) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 3.84%, trading at HK$18.93, with a turnover of HK$249.407 million.

On the evening of March 24, FOSUN PHARMA released its 2025 annual results. The group reported revenue of RMB 41.662 billion, an increase of 1.45% year-on-year. Net profit attributable to shareholders of the listed company was RMB 3.371 billion, up 21.69% compared to the previous year. Basic earnings per share were RMB 1.27, and the company proposed a cash dividend of RMB 3.90 per 10 shares (pre-tax). Additionally, net cash flow from operating activities was RMB 5.213 billion, representing a 16.45% increase year-on-year.

During the reporting period, the group's revenue from innovative drugs reached RMB 9.893 billion, a growth of 29.59% year-on-year. This segment now accounts for 33.16% of the pharmaceutical business revenue, an increase of 6.77 percentage points from the previous year. Core products such as Peijin, Oukangze, and Yikaida all achieved growth rates exceeding 30%, while products including Hanlikang, Hanquyou, and Hansizhuang maintained steady revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128354105?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128354105","market":"us","top_or_hot":-1,"title":"FOSUN PHARMA Shares Surge Over 5% as Annual Net Profit Climbs 21.69% to 3.37 Billion Yuan","media":"Deep News","content":"<p>FOSUN PHARMA (02196) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 3.84%, trading at HK$18.93, with a turnover of HK$249.407 million.</p>\n<p>On the evening of March 24, FOSUN PHARMA released its 2025 annual results. The group reported revenue of RMB 41.662 billion, an increase of 1.45% year-on-year. Net profit attributable to shareholders of the listed company was RMB 3.371 billion, up 21.69% compared to the previous year. Basic earnings per share were RMB 1.27, and the company proposed a cash dividend of RMB 3.90 per 10 shares (pre-tax). Additionally, net cash flow from operating activities was RMB 5.213 billion, representing a 16.45% increase year-on-year.</p>\n<p>During the reporting period, the group's revenue from innovative drugs reached RMB 9.893 billion, a growth of 29.59% year-on-year. This segment now accounts for 33.16% of the pharmaceutical business revenue, an increase of 6.77 percentage points from the previous year. Core products such as Peijin, Oukangze, and Yikaida all achieved growth rates exceeding 30%, while products including Hanlikang, Hanquyou, and Hansizhuang maintained steady revenue growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Shares Surge Over 5% as Annual Net Profit Climbs 21.69% to 3.37 Billion Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Shares Surge Over 5% as Annual Net Profit Climbs 21.69% to 3.37 Billion Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-03-25 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 3.84%, trading at HK$18.93, with a turnover of HK$249.407 million.</p>\n<p>On the evening of March 24, FOSUN PHARMA released its 2025 annual results. The group reported revenue of RMB 41.662 billion, an increase of 1.45% year-on-year. Net profit attributable to shareholders of the listed company was RMB 3.371 billion, up 21.69% compared to the previous year. Basic earnings per share were RMB 1.27, and the company proposed a cash dividend of RMB 3.90 per 10 shares (pre-tax). Additionally, net cash flow from operating activities was RMB 5.213 billion, representing a 16.45% increase year-on-year.</p>\n<p>During the reporting period, the group's revenue from innovative drugs reached RMB 9.893 billion, a growth of 29.59% year-on-year. This segment now accounts for 33.16% of the pharmaceutical business revenue, an increase of 6.77 percentage points from the previous year. Core products such as Peijin, Oukangze, and Yikaida all achieved growth rates exceeding 30%, while products including Hanlikang, Hanquyou, and Hansizhuang maintained steady revenue growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"","article_id":"1128354105","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128354105","pubTimestamp":1774407628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"FOSUN PHARMA (02196) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 3.84%, trading at HK$18.93, with a turnover of HK$249.407 million. On the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0012":"证金概念","BK1593":"医美概念股","BK0175":"白马股","BK0196":"行业龙头","02196":"复星医药","BK0188":"融资融券","BK0096":"民营医院","BK0187":"一线龙头","BK0183":"MSCI概念","BK0028":"国家队","BK0239":"医药制造","BK1515":"抗疫概念","BK1191":"制药","BK0060":"抗癌"},"translate_title":"复星医药股价大涨超5%年度净利润攀升21.69%至33.7亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 3.84%, trading at HK$18.93, with a turnover of HK$249.407 million.\nOn the evening of March 24, FOSUN PHARMA released its 2025 annual results. The group reported revenue of RMB 41.662 billion, an increase of 1.45% year-on-year. Net profit attributable to shareholders of the listed company was RMB 3.371 billion, up 21.69% compared to the previous year. Basic earnings per share were RMB 1.27, and the company proposed a cash dividend of RMB 3.90 per 10 shares (pre-tax). Additionally, net cash flow from operating activities was RMB 5.213 billion, representing a 16.45% increase year-on-year.\nDuring the reporting period, the group's revenue from innovative drugs reached RMB 9.893 billion, a growth of 29.59% year-on-year. This segment now accounts for 33.16% of the pharmaceutical business revenue, an increase of 6.77 percentage points from the previous year. Core products such as Peijin, Oukangze, and Yikaida all achieved growth rates exceeding 30%, while products including Hanlikang, Hanquyou, and Hansizhuang maintained steady revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128354105","isCrawlerRequest":true}